The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Epidemiology, Pathophysiology, and Prognostic Implications of Cystic Fibrosis–Related Diabetes
Open accessAbstract
Cystic fibrosis-related diabetes (CFRD) is the most common comorbidity in subjects with cystic fibrosis (CF).A consensus conference on CFRD was cosponsored by the Cystic Fibrosis Foundation (CFF), the American Diabetes Association (ADA), and the Pediatric Endocrine Society (PES) in September 2009.The committee's evidencebased recommendations for clinical management of CFRD are published in this issue of Diabetes Care.This review article describes the epidemiology, pathogenesis, and prognostic implications of CFRD. EpidemiologyCFRD is part of a continuum of glucose tolerance abnormalities, ranging from normal glucose tolerance (NGT), to impaired glucose tolerance (IGT), to CFRD without fasting hyperglycemia (CFRD FHϪ), to CFRD with fasting hyperglycemia (CFRD FHϩ) (Fig. 1).Unlike patients with type 1 diabetes, those with CFRD do not develop complete absence of insulin secretion.At the other end of the spectrum, few CF patients have truly normal glucose metabolism.Approximately 20% of children who are categorized as having NGT based on their fasting and 2-h oral glucose tolerance test (OGTT) glucose levels have glucose elevation Ͼ200 mg/dl (11.1 mmol/l) mid-OGTT, which is termed indeterminate glycemia (INDET) (1).As in the general population where INDET is a risk factor for progression to diabetes (2), INDET in children with CF is associated with early development of CFRD (1).Home continuous glucose monitoring (CGM) has shown that intermittent, asymptomatic hyperglycemia is common even in CF patients whose OGTT is normal, but the prognostic significance of these early impairments in glucose metabolism is unknown (3,4).Impaired fasting glucose has also been described in CF (5,6).CFRD is present in about 20% of adolescents and 40 -50% of adults with CF (7) (Fig. 2).It is rare in childhood but has been described in children of all ages including infants (8 -11).Beginning in the teenage years, the incidence is ϳ3%, with some but not all centers reporting an overall female predominance (7,12).In younger individuals CFRD FHϪ predominates, but the prevalence of fasting hyperglycemia rises with age (7).Diabetes is associated with more severe CF gene mutations, increasing age, worse pulmonary function, undernutrition, liver dysfunction, pancreatic insufficiency, and corticosteroid use (12-15).Pathophysiology CFRD shares features of both type 1 and type 2 diabetes, but has enough pathophysiological and clinical differences to warrant separate diagnostic classification (Table 1).As in type 1 diabetes, individuals with CFRD are not obese, it often occurs in young people, insulin insufficiency is the primary defect, and metabolic syndrome features (hyperlipidemia, hypertension, visceral adiposity) are not usually present.Clinical management is similar to type 1 diabetes in the honeymoon phase.As in type 2 diabetes, this is not an autoimmune disease, insulin resistance is present (albeit usually mild), and ketosis is rare.Genetically, CFRD may be related to type 2 diabetes, as described below.Insulin insufficiency.Reduced -cell mass leading to insulin insufficiency is the hallmark of CFRD.The CF gene defect leads to abnormal or absent CF transmembrane conductance regulator (CFTR), a chloride channel that also influences sodium and water transport.Thick, viscous secretions cause inflammation, obstruction, and destruction of small ducts in the lungs, pancreas, liver, and reproductive organs.Autopsy findings include fibrosis and atrophy of the pancreas with ϳ50% reduction of the total islet mass (16 -18).Multiple studies have shown impaired first-phase insulin secretion in response to glucose, arginine, or glucagon, even in subjects with .In response to oral glucose, the earliest defect is delayed insulin secretion, followed over time by a progressively diminished total insulin response (22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32).The -cell destruction is not complete and residual endogenous insulin secretion is present, so these patients are not prone to ketosis.The lack of ketosis may also be related to low glucagon levels.While fasting glucagon levels are normal, CF patients are not able to appropriately increase glucagon secretion in response to arginine or hypoglycemia (21,24), consistent with reduced ␣-cell mass.Incretin levels (gastric
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cystic Fibrosis–Related Diabetes: Current Trends in Prevalence, Incidence, and Mortality
Moran, A., Dunitz, J., Nathan, B., Saeed, A., Holme, B., & Thomas, W. (2009) · Diabetes Care · doi:10.2337/dc09-0586 · Cited by 648
Self-citationMILLA, C. E., WARWICK, W. J., & MORAN, A. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.3.9904075 · Cited by 367
Self-citationEpidemiology of cystic fibrosis-related diabetes
Marshall, B. C., Butler, S. M., Stoddard, M., Moran, A. M., Liou, T. G., & Morgan, W. J. (2005) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.12.039 · Cited by 327
Self-citationDiabetes mellitus associated with cystic fibrosis
Finkelstein, S. M., Wielinski, C. L., Elliott, G. R., Warwick, W. J., Barbosa, J., Wu, S.-C., & Klein, D. J. (1988) · The Journal of Pediatrics · doi:10.1016/s0022-3476(88)80315-9 · Cited by 290
Lanng, S., Thorsteinsson, B., Nerup, J., & Koch, C. (1992) · European Journal of Pediatrics · doi:10.1007/bf01957574 · Cited by 267
Insulin Therapy to Improve BMI in Cystic Fibrosis–Related Diabetes Without Fasting Hyperglycemia
Moran, A., Pekow, P., Grover, P., Zorn, M., Slovis, B., Pilewski, J., Tullis, E., Liou, T. G., Allen, H., & the Cystic Fibrosis Related Diabetes Therapy Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0585 · Cited by 240
Self-citationKoch, C., Rainisio, M., Madessani, U., Harms, H. K., Hodson, M. E., Mastella, G., McKenzie, S. G., Navarro, J., & Strandvik, B. (2001) · Pediatric Pulmonology · doi:10.1002/ppul.1142 · Cited by 218
Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections
Lanng, S., Thorsteinsson, B., Nerup, J., & Koch, C. (1994) · Acta Paediatrica · doi:10.1111/j.1651-2227.1994.tb13156.x · Cited by 210
Milla, C. E., Billings, J., & Moran, A. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2141 · Cited by 210
Self-citationMicrovascular Complications in Cystic Fibrosis–Related Diabetes
Schwarzenberg, S. J., Thomas, W., Olsen, T. W., Grover, T., Walk, D., Milla, C., & Moran, A. (2007) · Diabetes Care · doi:10.2337/dc06-1576 · Cited by 199
Self-citation
Cited by
Pancreatogenic Diabetes: Special Considerations for Management
Cui, Y., & Andersen, D. K. (2011) · Pancreatology · doi:10.1159/000329188 · Cited by 256
Diabetes mellitus secondary to pancreatic diseases (type 3c)—are we neglecting an important disease?
Ewald, N., & Bretzel, R. G. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2012.12.017 · Cited by 235
New insights into cystic fibrosis-related diabetes in children
Ode, K. L., & Moran, A. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70015-9 · Cited by 76
Self-citationCFTR is involved in the regulation of glucagon secretion in human and rodent alpha cells
Edlund, A., Pedersen, M. G., Lindqvist, A., Wierup, N., Flodström-Tullberg, M., & Eliasson, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-00098-8 · Cited by 63
Gilmour, J. A., Sykes, J., Etchells, E., & Tullis, E. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.04.008 · Cited by 51
Metadata
- Authors
- Moran, A., Becker, D., Casella, S. J., Gottlieb, P. A., Kirkman, M. S., Marshall, B. C., Slovis, B., & the CFRD Consensus Conference Committee
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-12-01
- Volume
- 33
- Issue
- 12
- Pages
- 2677-2683
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2167789521
- Cited by
- 258
- References
- 70
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epidemiology, Pathophysiology, and Prognostic Implications of Cystic Fibrosis–Related Diabetes. https://app.cochat.ai/papers/10.2337/dc10-1279
- The paper
- Moran, A., Becker, D., Casella, S. J., Gottlieb, P. A., Kirkman, M. S., Marshall, B. C., Slovis, B., & the CFRD Consensus Conference Committee. (2010). Epidemiology, Pathophysiology, and Prognostic Implications of Cystic Fibrosis–Related Diabetes. Diabetes Care. https://doi.org/10.2337/dc10-1279
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.